253 related articles for article (PubMed ID: 27722763)
1. Ustekinumab as Effective Treatment for Refractory Amicrobial Pustulosis of the Folds Associated with Crohn's Disease.
Al-Raddadi R; Frances C; Moguelet P; Bachmeyer C; Guégan S
Acta Derm Venereol; 2017 Mar; 97(3):389-390. PubMed ID: 27722763
[No Abstract] [Full Text] [Related]
2. Case of intractable scalp pustulosis with alopecia diagnosed with amicrobial pustulosis of the folds.
Miyakawa M; Yamaguchi Y; Hirokado M; Aihara M
J Dermatol; 2020 Feb; 47(2):e69-e70. PubMed ID: 31691329
[No Abstract] [Full Text] [Related]
3. Efficacy of Combination Vedolizumab and Ustekinumab for Refractory Crohn's Disease.
Huff-Hardy K; Bedair M; Vazquez R; Burstein E
Inflamm Bowel Dis; 2017 Oct; 23(10):E49. PubMed ID: 28858074
[No Abstract] [Full Text] [Related]
4. Amicrobial pustulosis of the folds affecting a young male without any accompanying autoimmune diseases.
Okuyama R; Masu T; Kumasaka N; Aiba S; Tagami H
Dermatology; 2008; 217(2):121-3. PubMed ID: 18477848
[No Abstract] [Full Text] [Related]
5. Ustekinumab for the treatment of Crohn's disease.
Hansen T; Targownik LE
Expert Rev Gastroenterol Hepatol; 2016 Sep; 10(9):989-94. PubMed ID: 27450626
[TBL] [Abstract][Full Text] [Related]
6. Ustekinumab for Resistant Pediatric Crohn Disease.
Rinawi F; Rosenbach Y; Assa A; Shamir R
J Pediatr Gastroenterol Nutr; 2016 Apr; 62(4):e34-5. PubMed ID: 25023579
[No Abstract] [Full Text] [Related]
7. Amicrobial pustulosis-like rash in a patient with Crohn's disease under anti-TNF-alpha blocker.
Lee HY; Pelivani N; Beltraminelli H; Hegyi I; Yawalkar N; Borradori L
Dermatology; 2011; 222(4):304-10. PubMed ID: 21757882
[TBL] [Abstract][Full Text] [Related]
8. Concentrations of Ustekinumab During Induction Therapy Associate With Remission in Patients With Crohn's Disease.
Soufflet N; Boschetti G; Roblin X; Cuercq C; Williet N; Charlois AL; Duclaux-Loras R; Danion P; Mialon A; Faure M; Paul S; Flourie B; Nancey S
Clin Gastroenterol Hepatol; 2019 Nov; 17(12):2610-2612. PubMed ID: 30851477
[TBL] [Abstract][Full Text] [Related]
9. Ustekinumab treatment for neutrophilic dermatoses associated with Crohn's disease: A multicenter retrospective study.
de Risi-Pugliese T; Seksik P; Bouaziz JD; Chasset F; Moguelet P; Gornet JM; Bourrier A; Amiot A; Beaugerie L; Francès C; Guégan S;
J Am Acad Dermatol; 2019 Mar; 80(3):781-784. PubMed ID: 30003991
[No Abstract] [Full Text] [Related]
10. Refractory Pyoderma Gangrenosum in a Patient With Crohn's Disease: Complete Response to Ustekinumab.
Nunes G; Patita M; Fernandes V
J Crohns Colitis; 2019 May; 13(6):812-813. PubMed ID: 30535292
[No Abstract] [Full Text] [Related]
11. Efficiency of Ustekinumab in Crohn's Disease with Severe Psoriasiform Rash Induced by Biotherapies in an Adolescent.
Bertrand V; El Haite A; Carré D
Pediatr Dermatol; 2017 Jul; 34(4):e214-e215. PubMed ID: 28436109
[TBL] [Abstract][Full Text] [Related]
12. Ustekinumab in a patient with pyoderma gangrenosum and refractory Crohn's disease.
García Cámara P; Zubiri Ara ML; García López S
Med Clin (Barc); 2019 Oct; 153(8):e35-e36. PubMed ID: 30795905
[No Abstract] [Full Text] [Related]
13. [Ustekinumab for the treatment of Crohn's disease -Indication of Ustekinumab according to efficacy and safety].
Ishihara S; Kawashima K; Kinoshita Y
Nihon Shokakibyo Gakkai Zasshi; 2019; 116(3):216-223. PubMed ID: 30853674
[No Abstract] [Full Text] [Related]
14. Is Ustekinumab the best treatment option in patients with Crohn's disease and coexistent multiple sclerosis?
Kapizioni C; Makris K; Kourkoulis P; Vrakas S; Michalopoulos G
Acta Gastroenterol Belg; 2019; 82(2):337. PubMed ID: 31314201
[No Abstract] [Full Text] [Related]
15. Emerging issues in the medical management of Crohn's disease.
Targownik LE; Coneys JG; Dhillon AS
Curr Opin Gastroenterol; 2016 Mar; 32(2):103-9. PubMed ID: 26839964
[TBL] [Abstract][Full Text] [Related]
16. Erosive pustular dermatosis of the scalp: a case treated successfully with isotretinoin.
Petersen BO; Bygum A
Acta Derm Venereol; 2008; 88(3):300-1. PubMed ID: 18480944
[No Abstract] [Full Text] [Related]
17. Papulopustular lesions of the face and scalp.
Wessbecher R; Technau-Hafsi K; Meiss F; Schauer F
J Dtsch Dermatol Ges; 2017 Jul; 15(7):755-757. PubMed ID: 28612972
[No Abstract] [Full Text] [Related]
18. Ustekinumab IV 6 mg/kg Loading Dose Re-induction Improves Clinical and Endoscopic Response in Crohn's disease: A Case Series.
Park S; Evans E; Sandborn WJ; Boland B
Am J Gastroenterol; 2018 Apr; 113(4):627-629. PubMed ID: 29610516
[No Abstract] [Full Text] [Related]
19. Elderly-onset Crohn's disease remarkably responsive to ustekinumab: a case report.
Iwamoto M; Kato K; Moriyama M
Int J Colorectal Dis; 2020 Feb; 35(2):355-359. PubMed ID: 31848740
[TBL] [Abstract][Full Text] [Related]
20. Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohn's Disease: Real-world Experience from a Multicenter Cohort Study.
Ma C; Fedorak RN; Kaplan GG; Dieleman LA; Devlin SM; Stern N; Kroeker KI; Seow CH; Leung Y; Novak KL; Halloran BP; Huang VW; Wong K; Blustein PK; Ghosh S; Panaccione R
Inflamm Bowel Dis; 2017 May; 23(5):833-839. PubMed ID: 28328624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
